NeonMind Biosciences Inc., is an integrated psychedelic drug development and wellness company focused on the therapeutic uses of psychedelics to address public health needs including obesity, weight management and mental health. At NeonMind Biosciences, we believe in “mind over matter” with the ultimate goal of supporting human health through our psychedelic drug development program and NeonMind-branded specialty mental health clinics.
In our pharmaceutical division, we are developing the first and only novel psilocybin-based drug candidates targeting obesity, a global health issue and one of the leading causes of death. Integral to the adoption of psychedelic medicine is the deployment of medical treatment services. NeonMind has established a medical services division which will be launching specialty mental health clinics in Canada that incorporate innovative, evidence-backed validated interventional psychiatry treatments for mood and anxiety disorders, a leading cause of disability in our society. Our goal is to help patients with weight management and mental health issues.
We are advancing psychedelic medicine and therapeutic treatments to improve bodies and minds through our two operating divisions.
Targeting Obesity with Revolutionary Psychedelic Compounds
NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind has an additional drug candidate, NEO-002, which employs low-dose psilocybin to control appetite. In addition, the Company has extensive U.S. and international patent applications pending which cover a wide spectrum of weight management conditions.
Enhancing Access to Specialized Interventional Psychiatry Treatments through NeonMind Clinics
Our medical services division is preparing to launch NeonMind-branded specialty mental health clinics across Canada, offering evidence-backed validated interventional psychiatry treatments tailored to local market needs. The Company has built a leading scientific advisory board, globally renowned for their expertise in practicing interventional psychiatry to treat mood and anxiety disorders. A medical services platform entrenched in the growing psychedelic sector, by improving access to validated treatments and incorporating the promising pipeline of psychedelic treatments as they are approved.
Stay informed and receive company updates straight to your inbox.
English